Targeting HER2 genomic alterations in non-small cell lung cancer

Oncogenic mutations and amplifications in the erythroblastic oncogene B (ERBB2), or human epidermal growth factor receptor 2 (HER2), have emerged as distinct oncogenic drivers and drug targets in non-small cell lung cancer (NSCLC). Each genomic alteration occurs in 2–4% of NSCLC by next generation s...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jie Zeng, Weijie Ma, Richard Benjamin Young, Tianhong Li
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://doaj.org/article/3f40bb24885440a89ee50c2dc8b49f30
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!